

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

DR5 antibody

RRID:AB_306551

Type: Antibody

Proper Citation

Abcam Cat# ab8416, RRID:AB_306551

Antibody Information

URL: http://antibodyregistry.org/AB_306551

Proper Citation: Abcam Cat# ab8416, RRID:AB_306551

Target Antigen: DR5 antibody

Host Organism: rabbit

Clonality: polyclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Western Blot; Immunohistochemistry - fixed; ICC/IF, IHC-P, WB

Antibody Name: DR5 antibody

Description: This polyclonal targets DR5 antibody

Target Organism: rat, mouse, human

Antibody ID: AB_306551

Vendor: Abcam

Catalog Number: ab8416

Record Creation Time: 20231110T081500+0000

Record Last Update: 20260829T033223+0000

Ratings and Alerts

No rating or validation information has been found for DR5 antibody.

No alerts have been found for DR5 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tian K, et al. (2026) METTL3-mediated fibroblast-like synoviocytes senescence promotes temporomandibular joint osteoarthritis progression. *Communications biology*, 9(1).

Mori K, et al. (2022) TNFRSF10A downregulation induces retinal pigment epithelium degeneration during the pathogenesis of age-related macular degeneration and central serous chorioretinopathy. *Human molecular genetics*, 31(13), 2194.

Jeong D, et al. (2021) Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2. *eLife*, 10.

Elmallah MIY, et al. (2020) Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP. *Cells*, 9(8).

Azhary JMK, et al. (2019) Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS. *Endocrinology*, 160(1), 119.

Shivange G, et al. (2018) A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. *Cancer cell*, 34(2), 331.